期刊文献+

肝外胆管癌的临床病理与预后分析 被引量:6

CLINICAL PATHOLOGY AND POSTOPERATIVE PROGNOSTIC FACTORS IN EXTRAHEPATIC CHOLANGIOCARCINOMA PATIENTS
暂未订购
导出
摘要 目的手术目前仍是肝外胆管癌(ECC)的唯一有效治疗手段。本研究通过研究ECC病人的各项临床病理特点,分析其与手术后病人预后的联系。方法分析2005年3月至2008年3月期间进行手术治疗的31例ECC病人。回顾性统计各项临床病理特点并用采用Kaplan-Meier分析其与病人预后联系。结果 ECC病人1、3、5年生存率分别为71.0%、18.5%、4.0%,平均生存时间为19.0个月。经根治性手术切除与姑息性手术切除治疗肝外胆管癌患者之间的生存率有显著性差异(P=0.049)。胆管周围组织浸润阴性者较胆管周围组织浸润阳性者的预后好(P=0.044),肿瘤分化程度越好的病人其预后越好(P=0.000)。结论我们的结果表明根治性手术、肿瘤有无浸润以及肿瘤的分化程度是ECC病人主要术后预后因素。 Objective Surgical resection was the only therapeutic modality for a permanent cure or a desirable prognosis for Extrahepatic cholangiocarcinoma (ECC). So far, postoperative prognostic factors of ECC patients remain not been well defined. Purposes of the present study were to identify these factors. Methods This study included 31 patients withintrahepatic cholangiocarcinoma from March 2005 to March 2008. We retrospectively reviewed and evaluated overall prognosis after resection. Their prognostic factors were identified by Kaplan - Meier statistical analysis. Results The average survival of ECCs after resection was 19.0 months and surgical treatment improved their prognosis. Univariate analysis showed that negative circumferential resection margin (P = 0. 049), infiltration to circumferential tissue (P = 0. 044), differentiation grade ( P = 0. 000) were significantly assocated with the prognosis of ECCs. Conclusions Our results suggest that resection margin, infiltration to circumferential tissue and differentiation grade were main factors that in fluenced survival of patients with ECC after resection.
出处 《肝胆外科杂志》 2011年第4期251-253,共3页 Journal of Hepatobiliary Surgery
关键词 肝外胆管癌 外科治疗 病理 生存率 entrahepatic cholangiocarcinoma surgical treatment pathology survival
  • 相关文献

参考文献2

二级参考文献23

  • 1Pode D, Golijanin D, Sherman Y, et al. Immunostaining of Lewis X in ceils from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol, 1998,159 (2) :389 -93.
  • 2Steplewska-Mazur K, Gabriel A, Zajecki W, et al. Breast cancer progression and expression of blood group-related tumor-associated antigens. Hybridoma, 2000,19 ( 2 ) : 129 - 33.
  • 3Minato H, Nakanuma Y, Terada T. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Histopathology, 1996,28 ( 5 ) :411 - 9.
  • 4Fontana R, Bregni M, Cipponi A, et al. Peripheral blood lymphoeytes genetieally modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009, 113:1651 -60.
  • 5Farhan H, Schuster C, Klinger M, et al. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen J Pharmacol Exp Ther, 2006, 319 (3) :1459 -66.
  • 6Atkins CD. CA 19-9 and Lewis antigens in pancreatic cancer. J Clin Oncol 2009 ;27:2572-3 ; author reply 3.
  • 7Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology, 2003, 50 (53) : 1669 - 74.
  • 8Juntavee A, Sripa B, Pugkhem A, et al. Expression of sialyl Lewis (a) relates to poor prognosis in eholangioearcinoma. World J Gastroenterol 2005,11:249 - 54.
  • 9Adachi M, Sekine T, Umemoto A, et al. Mechanism of clearance of circulating CA19-9 in rats. Tumour Biol, 1990, 11 (1-2) :51 -8.
  • 10Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci, 2005, 50(9) :1734 -40.

共引文献4

同被引文献19

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部